Management

The president is appointed by the board and is responsible for the Company’s day-to-day management in accordance with the board’s guidelines and instructions.

The president is responsible for keeping the board informed about the Company’s performance and reporting significant deviations from established business plans and about events with a major impact on the Company’s performance and operations, and for providing the board with relevant decision support in regard to, for example, establishments, investments and other strategic issues. Company management, headed by the Company’s president Jonas Jarvius, consists of people in charge of Q-linea’s key business areas.

Holdings as of December 28, 2022

Jonas Jarvius
CEO

Born: 1971
Chief Executive Officer since 2008

Jonas Jarvius has extensive experience in research and development in the field of in vitro diagnostics and the production of medical equipment. He has co-founded several companies, including Olink AB (OLK), and is one of the founders of Q-linea. He has held senior positions in various biotechnology companies for many years. In these roles, he has successfully managed projects related to molecular identification for security applications and the manufacturing, development, and production of medical products in various areas. In addition, he has been responsible for financing, development, and marketing strategies. He has experience in the certification of medical products for the European and American markets. In addition, he has been involved in several biotech startups that have grown into larger organizations. Jonas is the inventor of more than 15 patent families and applications and has published articles in leading scientific journals such as Nature Biotechnology, Nature Methods, PNAS, and Analytical Chemistry.

Education: PhD in molecular medicine, Uppsala University (2006); MSc in medical science, Uppsala University (1999).
Other ongoing assignments: Jonas Jarvius is chairman of of the board of Umbrella Science AB.

Holdings in the Company: Jonas Jarvius owns 273,152 shares and 30,000 stock options. He owns an additional 14,705 shares in the Company through his wholly owned Company Umbrella Science AB.

Mats Gullberg
Vice President, Research Director

Born: 1971
Employed by the Company since 2013, vice president since 2016 and research director since 2017

Mats Gullberg has extensive experience in product development and commercialisation and works with intellectual property issues in biotech companies. He has previously worked with methods of microbiology and molecular biology at Uppsala University. He has vast experience in R&D projects and in running projects to identify potential future products. Over the past ten years, he has been responsible for patent and intellectual property issues, previously at the Olink AB biotech company and since 2013 at Q-linea. Since 2017, he is also responsible for the Company’s research department.

Education: PhD in medical sciences, Uppsala University (2003); MSc in pharmaceutical bioscience (microbiology), Uppsala University (1995).
Other ongoing assignments: Mats Gullberg is a director at EMPE Diagnostics AB.

Holdings in the Company: Mats Gullberg owns 22,088 shares and 21,030 stock options in the Company.

Thomas Fritz
CCO

Born: 1964
Chief Commercial Officer since 2019

Thomas Fritz has more than 25 years of broad commercial experience in Microbiology, working in Clinical, Pharmaceutical and Industrial end markets. He was leading Marketing, Sales and Customer Service & Support organisations in various regions and was also Managing Director for a large manufacturing site.
In his previous role he served as Senior Director Commercial EMEA for the Microbiology Division of Thermo Fisher Scientific.

Education: Msc in Microbiology, Tuebingen University, Germany (1993)
Other ongoing assignments: Thomas Fritz is Co-Owner and Managing Director of ATC GmbH
Holdings in the Company: Thomas Fritz owns 4,500 shares and 21,030 stock options in the Company.

Anders Lundin
CFO

Born: 1964
Chief Financial Officer and Investor Relations since 2018

Anders Lundin has more than 20 years experience in financial work and leadership in international organisations operating in the medical technology and pharmaceutical industries. He has previously served as the CFO of a company listed on Nasdaq Stockholm and was also responsible for a listing on the Nasdaq Stock Market in the US and the associated raising of new equity capital.

Education: MSc in economics, Uppsala University (1992).
Other ongoing assignments: Anders Lundin is a founder and member of the board of directors of CFO Akuten AB.

Holdings in the Company: Through his wholly owned Company CFO Akuten AB he holds 27,363 shares in the Company.

Henrik Jacobsson
Chief Operating Officer

Born: 1969
Employed by the Company as Production Manager since 2021, Chief Operating Officer since 2022.

Henrik has more than 25 years of experience in leading positions mainly in operations and production. He helped create the convenience food concept and the company Gooh where he was responsible for building up the production and logistics operations. This work provided good experience in creating and scaling up the factory and organization. Henrik has also been production director at Lantmännen Cerealia and CEO of Swedish Meat’s subsidiary Esca Food Solutions.

Education: MSc in Industrial Economics, Linköping University (1995)

Other ongoing assignments: Board member of Jacobson Energi AB, Skånings Åsaka Vind AB and Vida Vind AB.

Holdings in the Company: Henrik Jacobson owns 200 shares and 3,570 stock options in the Company.

Tiziana Di Martino
Chief Medical Officer

Born: 1976
Chief Medical Officer since 2019

Tiziana Di Martino has more than 20 years experience in clinical practice, research and medical/clinical affairs positions in the microbial diagnostic industry. She has previously served as Regional Medical Affairs Manager at Abbott Molecular, Clinical and Scientific Affairs Manager EMEA at Abbott Point of Care and Head of Clinical Development EMEA at Accelerate Diagnostics. In these roles she has successfully managed clinical projects related to new product launches.

Education: MD degree, Università Cattolica del Sacro Cuore in Rome (2003); MSc in Toxicology, University of Surrey (2011), MBA degree, London Business School (2014).
Other ongoing assignments: Tiziana Di Martino has no other current assignments.

Holdings in the Company: Tiziana Di Martino owns 21,030 stock options in the Company.

Jonas Melin
Director Product Development

Born: 1976
Director Product Development since 2017

Jonas Melin has extensive R&D experience and a deep understanding of technical and regulatory issues. He has experience in project management and has successfully led projects from development to regulatory approval. His previous positions include project manager for Meritas D-Dimer test, Troponin test and BNP test and head of technical development of Meritas troponin I.

Education: PhD in engineering science, Uppsala University (2006); MSc in technical biology, Linköping University (2002).
Other ongoing assignments: Jonas Melin is a member of the board of directors of Melin Science AB.

Holdings in the Company: Jonas Melin owns 441 shares and 21,030 stock options in the Company.

Karl Sköld
Director Contract Development

Born: 1974
Director Contract Development since 2018

Karl Sköld has a background as a researcher in molecular biology and pharmaceutical life sciences at Uppsala University. In the years 2007 to 2016 he was active as founder, board member and research director of Denator AB, a company that has developed and sells systems for heat stabilisation of clinical samples. Furthermore, he is co-founder of Maurten AB, which develops energy and nutritional products to athletes and the healthcare industry. In 2017, he became CEO of Umbrella Science AB whose operations were acquired by Q-linea in the summer of 2018.

Education: PhD in pharmaceutical bioscience, Uppsala University, 2006.
Other ongoing assignments: Karl Sköld is a member of the board of directors of Hardcover AB and a deputy boardmember of Laminaria Group AB and Maurten AB.

Holdings in the Company: Karl Sköld owns 1000 stocks and 21,030 stock options in the Company.

Victoria Lerneryd
Manager QA/RA

Born: 1984
Employed by the Company since 2020, Manager QA/RA since 2020

Victoria Lerneryd has over 12 years of experience in quality assurance and regulatory affairs for medical devices, including developing and maintaining quality management systems, preparing regulatory product documentation, and regulatory reviews and applications. She has previously held positions as Quality Manager at St. Jude Medical and Quality & Regulatory Affairs Manager at Cavidi. These roles have included responsibility for compliance with regulatory requirements from product development to production and monitoring of products released to the market.

Education: MSc in Chemical Engineering, Uppsala University (2009).
Other ongoing assignments: Victoria Lerneryd has no other current assignments.
Holdings in the Company: Victoria Lerneryd owns 21,030 stock options in the company.

Ulrika Stolpe
HR Manager

Born: 1967
Employed by the company since 2012, HR Manager since 2019

Ulrika Stolpe prior to Q-linea has worked with finance, HR, and office operations at small and large national and international Life science companies since the 1990s. In 2012, she joined Q-linea as finance and office manager. Until 2019, she has driven the development of the company’s finances and personnel-administrative processes and has also taken a large part in work environment issues. In connection with the company IPO her work has been focused on HR where we can see a development from 2012 with a sharp increase in the number of employees.

Other ongoing assignments: Ulrika Stolpe has no other ongoing assignments.
Holdings in the Company: Ulrika Stolpe owns 3 441 shares and 21,030 stock options in the Company.

Anders Ljunggren
Manager Project Management Office, PMO
Born: 1981
Employed by the company since 2022 as Manager Project Management Office, PMO.

Anders Ljunggren has extensive experience in engineering project management, having worked at innovative R&D companies in industries like medical devices, industrial applications, consumer electronics, and space technology for the past 15 years. He has a track record of successfully managing B2B and in-house development projects, utilizing cross-functional team management skills and deep understanding of product development.

Education: MSc. in Materials engineering from Uppsala University, 2007.
Other ongoing assignments: Owner of Coego Consulting AB and Introspection AB.

Holdings in the Company: Anders Ljunggren holds 2,300 shares and 3,570 stock options in the Company.